Advertisement

Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases

      Background

      Botulinum toxin type A (BTA) (Botox) received Food and Drug Administration (FDA) approval for therapeutic treatment of strabismus and blepharospasm in 1989, cervical dystonia in 2000, and cosmetic treatment of glabellar wrinkles (Botox Cosmetic) in 2002. In 2002 alone there were approximately 1.1 to 1.6 million patients using cosmetic BTA. Our objective was to review adverse event (AE) reporting to the FDA after BTA administration.

      Methods

      We reviewed all (therapeutic and cosmetic use) serious (per FDA regulations) AEs reported to the FDA for the 13.5 years since licensure of the product (December 1989-May 2003) and nonserious AEs reported from December 2001 to November 2002. AEs are reported to the FDA through the MedWatch system.

      Results

      We reviewed 1437 AE reports; 406 followed therapeutic use of BTA (217 serious and 189 nonserious) and 1031 followed cosmetic use (36 serious and 995 nonserious). Reported AEs occurred predominantly in female patients, with a median age of 50 years. In the year December 2001 to November 2002, when both serious and nonserious reports were evaluated, the proportion of reports classified as serious was 33-fold higher for therapeutic than for cosmetic cases. The 217 serious AEs reported in therapeutic cases involved a wide spectrum of events and included all 28 reported deaths. Among cosmetic users, no deaths were reported and, of the 36 serious AEs, 30 were included as possible complications in the FDA-approved label. The remaining 6 serious AEs did not display a pattern suggesting a common causal relationship to BTA. Among the 995 cosmetic cases reported to have nonserious AEs, most commonly noted were lack of effect (623, 63%), injection site reaction (190, 19%), and ptosis (111, 11%).

      Conclusions

      Serious AEs were more likely to be reported for therapeutic than for cosmetic use, which may be related to higher doses, complicated underlying diseases, or both. Among cosmetic cases, few serious AEs were reported, and these were predominantly events that were previously recognized in clinical trials of BTA for the labeled use. This study is limited primarily by the incomplete nature of AE reporting by clinicians. Numerous departures from FDA-approved recommendations for drug dose, dilution, handling, site of injection, and storage were noted in these AE reports.
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Erbguth F.
        Botulinum toxin, a historical note.
        Lancet. 1998; 351: 1280
        • Scott A.B.
        • Rosenbaum A.
        • Collins C.C.
        Pharmacologic weakening of extraocular muscles.
        Invest Ophthalmol Vis Sci. 1973; 12: 924-927
        • Scott A.B.
        • Suzuki D.
        Systemic toxicity of botulinum toxin by intramuscular injection in the monkey.
        Mov Disord. 1988; 3: 333-335
        • Scott A.B.
        Botulinum toxin injection of eye muscles to correct strabismus.
        Trans Am Ophthalmol Soc. 1981; 79: 734-770
      1. PDR [package insert] (Allergan Botox). Available at: http://www.botox.com/site/professionals/prescribing_info/botox.asp. Accessed December 17, 2004

      2. PDR [package insert] (Allergan Botox Cosmetic). Available at: http://www.botox.com/site/professionals/prescribing_info/botox_cosmetic.asp. Accessed December 17, 2004.

        • Verheyden J.
        • Blitzer A.
        Other non-cosmetic uses of Botox.
        Dis Mon. 2002; 48: 357-366
        • O'Brien C.F.
        Treatment of spasticity with botulinum toxin.
        Clin J Pain. 2002; 18: S182-S190
        • Gracies J.
        • Elovic E.
        • McGuire J.R.
        • Simpson D.M.
        Traditional pharmacologic treatments for spasticity. Part I: local treatments. In Spasticity: etiology, evaluation, management and the role of botulinum toxin.
        Muscle Nerve Suppl. 1997; 6: S61-S91
        • Flett P.J.
        Rehabilitation of spasticity and related problems in childhood cerebral palsy.
        J Paediatr Child Health. 2003; 39: 6-14
        • Koman L.A.
        • Paterson Smith B.
        • Balkrishnan R.
        Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.
        Paediatr Drugs. 2003; 5: 11-23
        • Bang M.S.
        • Chung S.G.
        • Kim S.B.
        • Kim S.J.
        Change of dynamic gastrocnemius and soleus muscle length after block of spastic calf muscle in cerebral palsy.
        Am J Phys Med Rehabil. 2002; 81: 760-764
        • Yang T.F.
        • Fu C.P.
        • Kao N.T.
        • Chan R.C.
        • Chen S.J.
        Effect of botulinum toxin type A on cerebral palsy with upper limb spasticity.
        Am J Phys Med Rehabil. 2003; 82: 284-289
        • Polak F.
        • Morton R.
        • Ward C.
        • Wallace W.A.
        • Doderlein L.
        • Siebel A.
        Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.
        Dev Med Child Neurol. 2002; 44: 551-555
        • Dursun N.
        • Dursun E.
        • Alican D.
        The role of botulinum toxin A in the management of lower limb spasticity in patients with cerebral palsy.
        Int J Clin Pract. 2002; 56: 564-567
        • Berweck S.
        • Feldkamp A.
        • Francke A.
        • Nehles J.
        • Schwerin A.
        • Heinen F.
        Sonography-guided injection of botulinum toxin A in children with cerebral palsy.
        Neuropediatrics. 2002; 33: 221-223
        • Brashear A.
        • Gordon M.F.
        • Kassicieh V.D.
        • Marciniak C.
        • Do M.
        • Lee C.H.
        • et al.
        Botox Post-Stroke Spasticitiy Study Group. Intramuscular injections of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.
        N Engl J Med. 2002; 347: 395-400
        • Yelnik A.P.
        • Colle F.M.
        • Bonan I.V.
        • Lamotte D.R.
        Disabling overactivity of the extensor hallicus longus after stroke: clinical expression and efficacy of botulinum toxin type A.
        Arch Phys Med Rehabil. 2003; 84: 147-149
        • Childers M.K.
        • Wilson D.J.
        • Gnatz S.M.
        • Conway R.R.
        • Sherman A.K.
        Botulinum toxin type A use in piriformis muscle syndrome: a pilot study.
        Am J Phys Med Rehabil. 2002; 81: 751-759
        • Fishman L.M.
        • Anderson C.
        • Rosner B.
        Botox and physical therapy in the treatment of piriformis syndrome.
        Am J Phys Med Rehabil. 2002; 81: 936-942
        • Loder E.
        • Biondi D.
        Use of botulinum toxins for chronic headaches: a focused review.
        Clin J Pain. 2002; 18: S169-S176
        • Freund B.J.
        • Schwartz M.
        Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A.
        Headache. 2002; 42: 1033-1037
        • Rahmann Evers S.
        • Vollmer-Haase J.
        • Husstedt I.W.
        Treatment of headache with botulinum toxin A—a review according to evidence-based medicine criteria.
        Cephalalgia. 2002; 22: 699-710
        • Singer H.S.
        The treatment of tics.
        Curr Neurol Neurosci Rep. 2001; 1: 195-202
        • Sapienza C.M.
        • Cannito M.P.
        • Murry T.
        • Branski R.
        • Woodson G.
        Acoustic variations in reading produced by speakers with spasmodic dysphonia pre-Botox injection and within early stages of post-Botox injection.
        J Speech Lang Hear Res. 2002; 45: 830-843
        • Argoff C.E.
        A focused review on the use of botulinum toxins for neuropathic pain.
        Clin J Pain. 2002; 18: S177-S181
        • Heckmann M.
        • Heyer G.
        • Brunner B.
        • Plewig G.
        Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study.
        J Am Acad Dermatol. 2002; 47: 617-619
        • Glogau R.G.
        Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes.
        Clin J Pain. 2002; 18: S191-S197
        • Campanati A.
        • Penna L.
        • Guzzo T.
        • Menotta L.
        • Silvestri B.
        • Lagalla G.
        • et al.
        Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study.
        Clin Ther. 2003; 25: 298-308
        • Sevim S.
        • Sogu O.
        • Kaleagasi H.
        Botulinum toxin-A therapy for palmar and plantar hyperhidrosis.
        Acta Neurol Belg. 2002; 102: 167-170
        • Konrad H.
        • Karamfilov T.
        • Wollina U.
        Intracutaneous botulinum toxin A versus ablative therapy of Hailey-Hailey disease—a case report.
        J Cosmet Laser Ther. 2001; 3: 181-184
        • Wollina U.
        • Karamfilov T.
        Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison.
        J Eur Acad Dermatol Venereol. 2002; 16: 40-42
        • Neubrand M.
        • Scheurlen C.
        • Schepke M.
        • Sauerbruch T.
        Long-term results and prognostic factors in the treatment of achalasia with botulinum toxin.
        Endoscopy. 2002; 34: 519-523
        • Brant C.
        • Moraes-Filho J.P.
        • Siqueira E.
        • Nasi A.
        • Libera E.
        • Morais M.
        • et al.
        Intrasphincteric botulinum toxin injection in the treatment of chagasic achalasia.
        Dis Esophagus. 2003; 16: 33-38
        • Bansal R.
        • Nostrant T.T.
        • Scheiman J.M.
        • Koshy S.
        • Barnett J.L.
        • Elta G.H.
        • et al.
        Intrasphincteric botulinum toxin verses pneumatic balloon dilation for treatment of primary achalasia.
        J Clin Gastroenterol. 2003; 36: 209-214
        • Mitka M.
        Colon and rectal surgeons are trying Botox treatment, too.
        JAMA. 2002; 288: 439-440
        • Mentes B.B.
        • Irkorucu O.
        • Akin M.
        • Leventoglu S.
        • Tatlicioglu E.
        Comparison of botulinum toxin injection and lateral internal sphincterotomy for the treatment of chronic anal fissure.
        Dis Colon Rectum. 2003; 46: 232-237
        • Madalinski M.H.
        • Slawek J.
        • Duzynski W.
        • Zbytek B.
        • Jagiello K.
        • Adrich Z.
        • et al.
        Side effects of botulinum toxin injection for benign anal disorders.
        Eur J Gastroenterol Hepatol. 2002; 14: 853-856
        • Brisinda D.
        • Maria G.
        • Fenici R.
        • Civello I.M.
        • Brisinda G.
        Safety of botulinum neurotoxin treatment in patients with chronic anal fissure.
        Dis Colon Rectum. 2003; 46: 419-420
        • Spinelli P.
        • Gallardini G.
        Botulinum toxin type A (Dysport) for the treatment of Zenker's diverticulum.
        Surg Endosc. 2003; 17: 660
        • Tugnoli V.
        • Marchese Ragona R.
        • Eleopra R.
        • Quatrale R.
        • Capone J.G.
        • Pastore A.
        • et al.
        The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A.
        Clin Auton Res. 2002; 12: 174-178
        • Clark M.
        • Koppel D.A.
        Botulinum toxin in the treatment of Frey's syndrome.
        Br J Oral Maxillofac Surg. 2001; 39 ([letter]): 483
        • Ellies M.
        • Rohrbach-Volland S.
        • Arglebe C.
        • Wilken B.
        • Laskawi R.
        • Hanefeld F.
        Successful management of drooling with botulinum toxin A in neurologically disabled children.
        Neuropediatrics. 2002; 33: 327-330
        • Friedman A.
        • Potulska A.
        Botulinum toxin for treatment of parkinsonian sialorrhea.
        Neurol Neurochir Pol. 2001; 35: 23-27
        • von Lindern J.J.
        • Niederhagen B.
        • Appel T.
        • Berge S.
        • Reich R.H.
        New prospects in the treatment of traumatic and postoperative parotid fistulas with type A botulinum toxin.
        Plast Reconstr Surg. 2002; 109: 2443-2445
        • Smith C.P.
        • O'Leary M.
        • Erickson J.
        • Somogyi G.T.
        • Chancellor M.B.
        Botulinum toxin uretheral sphincter injection resolves urinary retention after pubovaginal sling operation.
        Int Urogynecol J Pelvic Floor Dysfunct. 2002; 13: 55-56
        • Schulte-Baukloh H.
        • Michael T.
        • Schobert J.
        • Stolze T.
        • Knispel H.H.
        Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results.
        Urology. 2002; 59: 325-328
        • Montoya F.J.
        • Riddell C.E.
        • Eaesar R.
        • Hauge S.
        Treatment of gustatory hyperlacrimation (crocodile tears) with injection of botulinum toxin into the lacrimal gland.
        Eye. 2002; 16: 705-709
        • Schwartz M.
        • Freund B.
        Treatment of temporomandibular disorders with botulinum toxin.
        Clin J Pain. 2002; 18: S198-S203
        • Rollnik J.D.
        • Meier P.N.
        • Manns M.P.
        • Goke M.
        Antral injections of botulinum A toxin for the treatment of obesity.
        Ann Intern Med. 2003; 138: 359-360
        • Difazio M.
        • Jabbari B.
        A focused review of the use of botulinum toxins for low back pain.
        Clin J Pain. 2002; 18: S155-S162
        • Kocs D.
        • Fendrick A.M.
        Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience.
        Am J Manag Care. 2003; 9: 393-402
        • Stone K.J.
        • Viera A.J.
        • Parman C.L.
        Off-label applications for SSRIs.
        Am Fam Physician. 2003; 68: 425-427
      3. Off-label use of tumor necrosis factor inhibitors on ankylosing spondylitis, ulcerative colitis, and psoriasis.
        TEC Bull. 2003; 20: 9-18
      4. American Society of Plastic Surgeons. Available at http://www.plasticsurgery.org/public_education/procedures/Botox.cfm. Accessed December 17, 2004.

      5. American Society for Dermatologic Surgery. Available at http://www.asds-net.org/Patients/patients-procedures.html. Accessed December 17, 2004.

      6. American Society of Aesthetic Plastic Surgery. Available at http://www.surgery.org/public/procedures-botoxing.php. Accessed December 17, 2004.

        • Gershon S.K.
        • Wise R.P.
        • Braun M.M.
        Adverse events reported with cosmetic use of botulinum toxin A.
        Pharmacoepidemiology Drug Safety. 2001; 10: S135-S136
        • Brewer T.
        • Colditz G.A.
        Postmarketing surveillance and adverse drug reactions: current perspectives and future needs.
        JAMA. 1999; 281: 824-829
        • Kennedy D.
        • Goldman S.
        • Lillie R.
        Spontaneous reporting in the United States.
        in: Strom B.L. Pharmacoepidemiology. 3rd ed. Wiley, Chicester2000: 151-174
        • Baum C.
        • Kweder S.
        • Anello C.
        The spontaneous reporting system in the United States.
        in: Strom B.L. Pharmacoepidemiology. 2nd ed. John Wiley and Sons, New York1994: 125-137
        • Braun M.M.
        • Patriarca P.A.
        • Ellenberg S.S.
        Syncope after immunization.
        Arch Pediatr Adolesc Med. 1997; 151: 255-259